Open AccessForgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro
Author(s) -
Rima Acosta,
Michelle L D’Antoni,
Andrew Mulato,
Stephen R. Yant,
Tomáš Cihlář,
Kirsten White
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02038-21
Subject(s) - cmin , dolutegravir , emtricitabine , rilpivirine , tenofovir alafenamide , pharmacology , regimen , medicine , virology , integrase inhibitor , drug resistance , integrase , pharmacokinetics , cmax , human immunodeficiency virus (hiv) , biology , viral load , microbiology and biotechnology , antiretroviral therapy
The integrase strand transfer inhibitor (INSTI)-based regimens bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), dolutegravir (DTG)+FTC/TAF, DTG/lamivudine (3TC), and DTG/rilpivirine (RPV) are all approved for treatment of HIV-infected patients, with various limitations. Here, time toin vitro viral breakthrough (VB) and resistance barrier using simulated human drug exposures at either full or suboptimal treatment adherence to each regimen were compared.